1. Home
  2. NVRI vs KURA Comparison

NVRI vs KURA Comparison

Compare NVRI & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enviri Corporation

NVRI

Enviri Corporation

HOLD

Current Price

$18.39

Market Cap

1.5B

Sector

Miscellaneous

ML Signal

HOLD

Logo Kura Oncology Inc.

KURA

Kura Oncology Inc.

HOLD

Current Price

$8.67

Market Cap

830.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVRI
KURA
Founded
1853
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
830.1M
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
NVRI
KURA
Price
$18.39
$8.67
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$26.88
AVG Volume (30 Days)
1.3M
1.3M
Earning Date
05-26-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
2.88
EPS
N/A
N/A
Revenue
$2,240,358,000.00
$53,883,000.00
Revenue This Year
$5.30
$88.72
Revenue Next Year
$4.15
$60.02
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.72
$5.41
52 Week High
$19.48
$12.49

Technical Indicators

Market Signals
Indicator
NVRI
KURA
Relative Strength Index (RSI) 46.50 53.40
Support Level $17.86 $8.09
Resistance Level $18.62 $10.50
Average True Range (ATR) 0.59 0.33
MACD -0.11 0.12
Stochastic Oscillator 57.68 94.05

Price Performance

Historical Comparison
NVRI
KURA

About NVRI Enviri Corporation

Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Share on Social Networks: